Singapore, Nov. 17 -- ImmunoScape, an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, has announced an exclusive in-licensing deal with US-based Cue Biopharma Incto lead the development of a distinct new class of therapies to attack solid tumour cancers.

The deal provides ImmunoScape with exclusive access to Cue Biopharma's clinical-stage Immuno-STAT(R) molecules in oncology.

By combining Cue Biopharma's technology with its precision T cell receptor (TCR) therapy, ImmunoScape is pioneering a new "Seed-and-Boost" approach to immunotherapy, that addresses the shortcomings of current cell therapies by enabling potent in vivo expansion of infused tumor targeting T-cells-...